Table 1 Comparison among the Best Overall Response Rate, the Disease Control Rate, and the duration of response of the three randomized phase II-III studies which utilized ipilimumab (MDX010-08, MDX010-20, and CA184-024)
From: Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
| Â | MDX010-08 | MDX010-20 | CA184-024 | ||||
|---|---|---|---|---|---|---|---|
| Â | DTIC + Ipi | Ipi | Ipi + gp100 | Ipi | gp100 | DTIC + Ipi | DTIC |
Patients (N.) | (35) | (37) | (403) | (137) | (136) | (250) | (252) |
BORR | 14.3% | 5.4% | 5.7% | 10.9% | 1.5% | 15.2% | 10.3% |
DCR | 37.1% | 21.6% | 20.1% | 28.5% | 11.0% | 33.2% | 30.1% |
Median Duration of BOR in months (CI) | 5.7* (0.7-19.2) | 10.8* (3.0-25.4) | 11.5 (5.5-NR) | NR (28.1-NR) | NR (2.0-NR) | 19.3 (not reported) | 8.1 (not reported) |